Histone Deacetylase 2 - Pipeline Review, H1 2020
Histone Deacetylase 2 - Pipeline Review, H1 2020
SUMMARY
According to the recently published report 'Histone Deacetylase 2 - Pipeline Review, H1 2020'; Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.
The report 'Histone Deacetylase 2 - Pipeline Review, H1 2020' outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 13 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mycosis Fungoides, B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Huntington Disease, Lewy Body Dementia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Parkinson's Disease, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Blood Cancer, Bone Disorders, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Epithelial Ovarian Cancer, Gallbladder Cancer, Gliosarcoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Fibrosis, Lung Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pick Disease, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus and Thalassemia.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Histone Deacetylase 2 - Pipeline Review, H1 2020'; Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.
The report 'Histone Deacetylase 2 - Pipeline Review, H1 2020' outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 13 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mycosis Fungoides, B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Huntington Disease, Lewy Body Dementia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Parkinson's Disease, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Blood Cancer, Bone Disorders, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Epithelial Ovarian Cancer, Gallbladder Cancer, Gliosarcoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Fibrosis, Lung Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pick Disease, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus and Thalassemia.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Overview
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Development
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Assessment
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Drug Profiles
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Product Development Milestones
Appendix
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Overview
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Development
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Assessment
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Drug Profiles
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by 4D Pharma Plc, H1 2020
Pipeline by 4SC AG, H1 2020
Pipeline by Alkermes Plc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Chipscreen Biosciences Ltd, H1 2020
Pipeline by Curis Inc, H1 2020
Pipeline by Italfarmaco SpA, H1 2020
Pipeline by Jubilant Biosys Ltd, H1 2020
Pipeline by Medivir AB, H1 2020
Pipeline by MEI Pharma Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Oceanyx Pharmaceuticals Inc, H1 2020
Pipeline by Regenacy Pharmaceuticals LLC, H1 2020
Dormant Products, H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by 4D Pharma Plc, H1 2020
Pipeline by 4SC AG, H1 2020
Pipeline by Alkermes Plc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Chipscreen Biosciences Ltd, H1 2020
Pipeline by Curis Inc, H1 2020
Pipeline by Italfarmaco SpA, H1 2020
Pipeline by Jubilant Biosys Ltd, H1 2020
Pipeline by Medivir AB, H1 2020
Pipeline by MEI Pharma Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Oceanyx Pharmaceuticals Inc, H1 2020
Pipeline by Regenacy Pharmaceuticals LLC, H1 2020
Dormant Products, H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
4D Pharma Plc
4SC AG
Alkermes Plc
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Curis Inc
Italfarmaco SpA
Jubilant Biosys Ltd
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
Regenacy Pharmaceuticals LLC
Shuttle Pharmaceuticals Inc
Yungjin Pharm Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
4D Pharma Plc
4SC AG
Alkermes Plc
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Curis Inc
Italfarmaco SpA
Jubilant Biosys Ltd
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
Regenacy Pharmaceuticals LLC
Shuttle Pharmaceuticals Inc
Yungjin Pharm Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
